Thus, we categorized the cohort into two groups: the TERTp+/TP53+ group and the TERTp‐/TP53+ group, and analyzed the relationship between the two groups and clinicopathological characteristics of HCC patients (Table 2). The gene discussed is TP53; the disease is hepatocellular carcinoma.